It never ceases to amaze me that some people refuse to believe that corporations intentionally suppress safety information about their products due to marketing concerns. Unfortunately, it keeps happening again, and again, and again. This time, with Pradaxa:
Publishing the research results, she warned, could make it “extremely difficult” for the company to defend its
Right now, thousands of vaginal mesh lawsuits are pending in the U.S. District Court for the Southern District of West Virginia. Just as the criminal justice system would collapse if every criminal case went to trial, so too would our civil justice system collapse if every vaginal mesh case went to trial. The vaginal mesh
Two articles popped up in my inbox today. The first tells the sad story of a man who died after taking a supplement known as “Stiff Nights.”
“A Kansas City man died last year after taking an unapproved erectile dysfunction drug allegedly labeled as a dietary supplement, a Jackson County lawsuit says.
David R.
This shows that the FDA is more interested in protecting pharmaceutical companies than patients. Note how Woodcock doesn’t want to force new trials because that requires human experimentation, which has risk. A smarter regulator would realize that the risks increase in proportion to the size of the user base of the drug. And allowing any
I knew there was a reason I got licensed to practice law in consumer-friendly Washington:
A Washington state court yesterday denied Intuitive’s bid to throw out a lawsuit over the death of a patient operated on using the company’s da Vinci surgical system, according to court filings. The judge found the state’s product-liability laws
So, the Supreme Court will decide two interesting cases. The one below will decide whether or not a brand name manufacturer can simply pay generic companies not to bring generic drugs to market:
WASHINGTON (AP) — Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay
Here’s a little more in-depth analysis of the generic drug argument before SCOTUS:
Andre Mura, litigation counsel at the Center for Constitutional Litigation in Washington, D.C., said the government’s argument was troubling. “There were suggestions that the FDA shouldn’t be second-guessed, but as the Court said in Wyeth v. Levine, the FDA approval process
Just imagine the sleazy sales manager who wrote the e-mail below”
Company e-mails introduced in a lawsuit filed against Intuitive in Kitsap County, Washington, suggest salesmen lobbied hospitals to scale back doctor training. One manager’s e-mail lauded a salesman for persuading a hospital that five supervised operations were too many. In another, a manager
On the one hand it’s disappointing to see them give up the fight. On the other, at least this won’t lead to a SCOTUS ruling that strips the FDA of more power. The fear of such a ruling is why I suspect the FDA gave up.
(Reuters) – The government has dropped its push for
More on generic liability:
During a one-hour oral argument justices questioned whether federal law, in this case the requirement that generics have same design as the name-brand version, prevents plaintiffs from making such claims under state law.
Some justices signaled concern about juries making sweeping judgments about the effectiveness of drugs while others